When and how can Healthcare Database Analyses replace RCTs in marketed medications?
|
|
- Claire Little
- 6 years ago
- Views:
Transcription
1 Third Plenary WHEN DO WE REALLY NEED RANDOMIZED CONTROLLED TRIALS? Sebastian Schneeweiss, MD, ScD Brigham & Women s Hospital and Harvard Medical School Boston, MA, USA When and how can Healthcare Database Analyses replace s in marketed medications? Sebastian Schneeweiss Division of Pharmacoepidemiology and Pharmacoeconomics, Dept. of Medicine, Brigham & Women s Hospital/ Harvard Medical School Disclosures: PI, Harvard Brigham & Women s Hospital Drug Safety Research Center (FDA) Co Chair, Methods Core of the FDA Sentinel System Consulting in past year: WHISCON LLC, Aetion Inc. (incl. equity) PI of research contracts to the Brigham & Women s Hosp.: Bayer, Genentech, Boehringer Ingelheim Grants/contracts from NIH, AHRQ, PCORI, FDA, IMI Advising FDA, EMA, PCORI, Health Canada 1
2 Real World Data in Pharmacoepidemiology Non experimental data 10% Research data Data collected PRIMARILY for research 90% Transactional data Data used SECONDARILY for research Example For purpose Data specifically for study purpose Framingham Study Cardiovas Health Study Slone Birth Defects Study Some registries Other purpose Data intended for other studies Nurses Health Study 1 Some registries Other purpose Clinical documentation EHR based studies NDI linkage Lab test databases Some registries Administrative Claims data studies Geocoding/census Database Studies CV Safety Example: BART 2
3 CV Safety Example: BART CV Safety Example: ENTRACTE Effectiveness Example: 3
4 Effectiveness Example: Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) 4
5 Effectiveness Example: Why did these database studies come to the HR = 0.66 ( ) HR = 0.77 ( ) same causal conclusion? Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) How confident are we that the study we plan will get it right? 5
6 Less helpful summarization of vs. non experim l: Hemkens et al. BMJ 2016 A corrected re analysis of Hemkens et al. BMJ 2016 Franklin JM, Rothman K, et al.: A Bias in the Evaluation of Bias Comparing Randomized Trials with Non experimental Studies. Epidemiology Methods 2017 Re analysis of treatment effects on mortality in RCD studies and s. For each clinical question, we present the relative odds ratio reported in trial evidence versus the corresponding RCD study. Effect estimates are presented when inverting treatment groups and ORs whenever the OR>1. 6
7 Following 3 guide posts 1. Active Comparator, same treatment modality 2. New Users 3. High-dimensional proxy adjustment result in 1. Clinical relevance 2. Meaningful causal statement 3. High validity 7
8 How to Investigatorcontrolled Datadependent 4. Outcome observable with specificity 5. Achieve covariate balance 6. Avoid known design flaws: a) Avoid immortal time bias b) Avoid adjusting for causal intermediates c) Avoid reverse causation d) Deal with time-varying hazards 7. Do robustness checks When to work with non experimental RWD studies for regulatory and payer decision making? Active comparator Same treatment modality comparator Outcome measureable How to Consider points 4 7 RWE software platforms improve quality, transparency Conduct feasibility analyses; Proceed if balance achieved in measured and UNMEASURED 8
9 When to work with non experimental RWD studies for regulatory and payer decision making? Active comparator Same treatment modality comparator Outcome measureable How to Consider points 4 7 RWE software platforms improve quality, transparency Conduct feasibility analyses; Proceed if balance achieved in measured and UNMEASURED There are >15 CV safety trials currently committed to FDA. If few of those could be replaced with RWE studies this would be a game changer. Effectiveness Example: HR = 0.66 ( ) HR = 0.77 ( ) What do we need to show to develop the confidence that the next RWE study will get it right? 9
10 Baseline Randomization Controlled measurement Seeming simplicity of design No randomization Non standardized observations Seeming complexity of design A priori confidence in causal conclusions What is our confidence level? What do we need to do to gain a priori confidence in causal conclusions? 10
Pharmacovigilance & Signal Detection
Pharmacovigilance & Signal Detection 30 th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Pre-conference educational session Thursday, October 23, 2014; 2:00-6:00pm Semi-automated,
More informationFramework for FDA s Real-World Evidence Program
Framework for FDA s Real-World Evidence Program Jacqueline Corrigan-Curay, J.D., M.D. Director, Office of Medical Policy Center for Drug Evaluation and Research Food and Drug Administration March 15, 2019
More informationLarge electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project
Large electronic healthcare databases for medical product safety surveillance The U.S. FDA Mini-Sentinel project Darren Toh, ScD Department of Population Medicine Harvard Medical School and Harvard Pilgrim
More informationUsing local RWD to drive global therapeutic advancements.
Using local RWD to drive global therapeutic advancements. Helsinki, 30 th Nov 2016 Mike Spencer, Head of Real World Evidence, EMEA, Janssen The following represent my own views and not necessarily those
More informationThe Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
The Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Owen Faris, Ph.D. Director, Clinical Trials Program Office of Device Evaluation Center for Devices and Radiological
More informationRegulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling
Presentation title Date 1 Regulatory challenges and opportunities for the use of Real World Evidence for drug registration and labelling Marianne Bork Samuelsen, Msc Pharm Regulatory Affairs Novo Nordisk
More informationCRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action
CRNs as Foundational Blocks of the National Evaluation System for Medical Devices: A Call to Action Danica Marinac Dabic, MD, PhD Director, Division of Epidemiology Summary FDA Strategic Priorities: 2016
More informationPrecision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease
Precision Medicine: Harnessing Biomedical Data to Improve the Prediction, Prevention, Diagnosis and Treatment of Disease Session #61, February 20, 2017 Jason Levine, MD, Assoc. Director of Clinical Informatics,
More informationEuropean contribution to the RWD/RWE debate. Alasdair Breckenridge July 2018
European contribution to the RWD/RWE debate Alasdair Breckenridge July 2018 Sources UK Academy of Medical Sciences(AMS) workshops European Medicines Agency (EMA) Innovative Medicines Initiative (IMI) projects
More informationCurrent State of Endpoint Adjudication in Device Trials Academic View
HARVARD MEDICAL SCHOOL Current State of Endpoint Adjudication in Device Trials Academic View CSRC/MDEpiNet Device Adjudication March 11, 2016 Donald E. Cutlip, MD Harvard Clinical Research Institute Smith
More informationData Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle
Data Quality in the Real World: Ensuring Integrity across the Medical Device Lifecycle Moderated by Karen Conway, GHX Panelists: Steven Luxenberg, MD, U.S. FDA CDRH Dennis Black, BD Robert Lynch, Franciscan
More information1. POLICY STATEMENT: 2. BACKGROUND:
POLICY #: RCO-201 Page: 1 of 5 1. POLICY STATEMENT: All Food and Drug Administration (FDA) regulated research conducted under an Investigational New Drug Application (IND) and managed within DF/HCC requires
More informationEverything You Wanted to Know About ClinicalTrials.gov*
Everything You Wanted to Know About * Deborah A. Zarin, MD Director, National Library of Medicine (*But Were Afraid to Ask) DISCLAIMER Views are mine and do not necessarily represent views of NIH or HHS
More informationTHE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION
THE IMPACT OF THE AFFORDABLE CARE ACT (ACA) ON CANCER RESEARCH, CARE, AND PREVENTION William S. Dalton, PhD, MD AACR April 17, 2016 Designing a Federated Model To Support Research & Healthcare Offices
More informationOverview of FDA s Sentinel Initiative
Overview of FDA s Sentinel Initiative Judy Racoosin, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration September
More informationPotential Steps in Active Surveillance
Background The Sentinel System will augment FDA s postmarket safety assessment capabilities by enhancing its capacity to conduct active surveillance at the population level. Conducting active surveillance
More informationEmerging study designs - The need of real world evidence to validate safety and efficacy results from clinical trials
14MAR2018 1 Emerging study designs - The need of real world evidence to validate safety and efficacy results from clinical trials Symposium Drug Research Academy March 14 2018 Atheline Major-Pedersen MD,
More informationValidating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality Hua Xu, PhD School of Biomedical Informatics, UTHealth JAMIA Journal
More information2018 Data Science Summit: The Economics Of Artificial Intelligence In Healthcare
May 30, 2018 2018 Data Science Summit: The Economics Of Artificial Intelligence In Healthcare Making AI Work In Clinical Practice Bibb Allen, MD FACR Chief Medical Officer ACR Data Science Institute OVERVIEW
More informationReal World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST)
Real World Evidence Generation in the 21 st Century: National Evaluation System for health Technology (NEST) Bill Murray, President & CEO IDEAL Conference Presentation May 5, 2017 1 www.mdic.org Vision
More informationPublic - Private Partnerships in Europe and ENCePP Initiative
Public - Private Partnerships in Europe and ENCePP Initiative Henry Fitt Section Head, Co-ordination & Networking, Pharmacovigilance and Risk Management European Medicines Agency 22nd Annual EuroMeeting
More informationRWE Best Practices: Lessons from the US
RWE Best Practices: Lessons from the US Canadian Assoc. for Population Therapeutics Nancy A. Dreyer Chief Scientific Officer December 13, 2018 Copyright 2017 IQVIA. All rights reserved. MEET THE SPEAKER
More informationRWE Best Practices: Lessons from the US
RWE Best Practices: Lessons from the US Canadian Assoc. for Population Therapeutics Nancy A. Dreyer Chief Scientific Officer December 13, 2018 Copyright 2017 IQVIA. All rights reserved. MEET THE SPEAKER
More informationLeveraging Prognostic Baseline Variables in RCT. Precision in Randomized Trials
Leveraging Prognostic Baseline Variables to Gain Precision in Randomized Trials Michael Rosenblum Associate Professor of Biostatistics Johns Hopkins Bloomberg School of Public Health (JHBSPH) Joint work
More informationReal-World Data & Life Science Analytics Congress
25 th -26 th October 2018, Boston Real-World Data & Life Science Analytics Congress Event Overview As healthcare organizations move forward into the bold new world of value-based payments, they need to
More informationDon Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201
October 17, 2018 Don Rucker, M.D. National Coordinator Office of the National Coordinator for Health Information Technology 330 C Street, SW Washington, DC 20201 Re: Request for Information Regarding the
More informationUsing Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice. Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology
Using Real-World Evidence (RWE) for Regulatory Decision Making and Pracatice Danica Marinac-Dabic, MD, PhD Director, Division of Epidemiology Summary RWE context Selected Examples of Early Successes and
More informationNESTcc Call for Concepts Public Webinar. Rachael L. Fleurence, PhD. NESTcc Executive Director January 4, 2018
Dial-In: +1-415-655-0002 Access code: 662 348 083 Join Online: https://mdic.webex.com/mdic/ onstage/g.php?mtid=edc86dc3 ee6a3970422222c725600570b NESTcc Call for Concepts Public Webinar Rachael L. Fleurence,
More informationWhat We Learned Running Investigator Initiated Trials
What We Learned Running Investigator Initiated Trials James D. Lewis, MD, MSCE Division of Gastroenterology Center for Clinical Epidemiology & Biostatistics University of Pennsylvania Hans Herfarth, MD,
More informationSignal Detection Quantitative Analysis of Safety Data. Dr. Yusuf Tanrikulu Basel, 29th November 2016
Signal Detection Quantitative Analysis of Safety Data Dr. Yusuf Tanrikulu Basel, 29th November 2016 Contents Regulatory background Goals of signal detection Data sources Methods Recent developments 2 Regulatory
More informationMissing Data Handling in Non-Inferiority & Equivalence Trials
Missing Data Handling in Non-Inferiority & Equivalence Trials A systematic review Brooke A Rabe Graduate Interdisciplinary Program in Statistics The University of Arizona, Tucson, USA PSI s Pharmaceutical
More informationUse of Real World Data in Development Programmes
Use of Real World Data in Development Programmes Dr Alison Cave and Dr Francesca Cerreta Industry Stakeholder Platform on Research and Development Support 25 April 2017 An agency of the European Union
More informationComparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data
Comparing the use of OMOP and Sentinel CDMs for Drug Safety Implications for European Data Andrew Bate Senior Director, Epidemiology Group Lead, Analytics A Common Data Model for Europe? Why? Which? How?
More informationPCWP and HCPWP work programmes for 2013
PCWP and HCPWP work programmes for 2013 Presented by: Ivana Silva and Nathalie Bere P-MI-PIN Public Information and Stakeholder Networking An agency of the European Union Meetings scheduled for 2013 27
More informationRAPID Phase 1 Deliverables Use Cases, Flow Diagrams
RAPID Phase 1 Deliverables Use Cases, Flow Diagrams James E. Tcheng, MD Duke Clinical Research Institute Durham, NC RAPID Think Tank 14 September 2016 1 Use Cases: Background & Rationale Why Use Cases?
More informationProof of Concept Vs Proof of Value
Evidence Requirements Supporting Critical Decisions in Pharmacotherapeutics: Proof of Concept Vs Proof of Value RG Peterson MD, PhD, MPH Executive Director Drug Safety and Effectiveness Network Canadian
More informationIncorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting
Incorporating Evidence from Clinical Experience into Regulatory Decision- Making: A Pragmatic Approach to Randomization in the Clinical Setting Washington Plaza Hotel Washington, DC January 15, 2016 Meeting
More informationEFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY
EFPIA-PHRMA PRINCIPLES FOR RESPONSIBLE CLINICAL TRIAL DATA SHARING REPORT ON THE 2016 MEMBER COMPANY SURVEY PREAMBLE The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the
More informationJeffrey Brown, PhD. November 12, 2013 Department of Population Medicine Harvard Pilgrim Health Care Institute/ Harvard Medical School
info@mini-sentinel.org 1 Biosimilar Collective Intelligence System: Utilizing Data Consortiums to Prove Safety and Effectiveness of Biosimilars Reviewing current landscape of existing data consortiums:
More informationPharmacoepidemiology. Dr. Mahyar Etminan Scientist Department of Medicine, UBC
Pharmacoepidemiology Dr. Mahyar Etminan Scientist Department of Medicine, UBC Contacts Email: metminan@shaw.ca Tel: 604-875-2000 (7954) What is pharmacoepidemiology? study of drug efficacy, toxicity and
More information1201 Maryland Avenue SW, Suite 900, Washington, DC ,
1201 Maryland Avenue SW, Suite 900, Washington, DC 20024 202-962-9200, www.bio.org June 6, 2008 Dockets Management Branch (HFA-305) Food and Drug Administration 5600 Fishers Lane, Rm. 1061 Rockville, MD
More informationFDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency
FDA Experience with the Sentinel Common Data Model: Addressing Data Sufficiency Michael D. Nguyen, MD Office of Surveillance and Epidemiology Center for Drug Evaluation and Research US Food and Drug Administration
More informationUDI in the US. Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration. 19 October 2017
UDI in the US Ms. Terrie Reed, Senior Advisor for UDI Adoption U.S. Food and Drug Administration 19 October 2017 UDI: Regulatory Update Terrie L. Reed, MS. Ind. Engineering Center for Devices and Radiological
More informationToward Greater Transparency and Rigor
Toward Greater Transparency and Rigor TRANSPARENCY: ClinicalTrials.gov registration and results reporting The Center for Clinical & Translational Science 205.934.7442 ccts@uab.edu www.uab.edu/ccts @cctsnetwork
More informationBETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular
BETRIXABAN TO PREVENT PE, DVT, STROKE: MEDICALLY ILL PATIENTS Samuel Z. Goldhaber, MD Director, Thrombosis Research Group Section Head, Vascular Medicine Cardiovascular Division Brigham and Women s Hospital
More informationOctober 25, Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers Lane, Room 1061 Rockville, MD 20852
701 Pennsylvania Avenue, NW Suite 800 Washington, D.C. 20004 2654 Tel: 202 783 8700 Fax: 202 783 8750 www.advamed.org Division of Dockets Management (HFA-305) Food and Drug Administration 5630 Fishers
More informationCENTRAL NERVOUS SYSTEM (CNS) BIOMARKERS: TECHNOLOGIES AND GLOBAL MARKETS
CENTRAL NERVOUS SYSTEM (CNS) : TECHNOLOGIES AND GLOBAL MARKETS BIO074C March 2016 Jackson Highsmith Project Analyst ISBN: 1-62296-246-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
More informationReal World Evidence how patient groups can contribute and how to engage patient groups in clinical research
Real World Evidence how patient groups can contribute and how to engage patient groups in clinical research ERIC LOW INDEPENDENT HEALTHCARE CONSULTANT CHAIRMAN AMYLOIDOSIS RESEARCH CONSORTIUM UK FOUNDER
More informationAugust 25, Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm Rockville, MD 20852
August 25, 2014 Dockets Management Branch (HFA-305) Food and Drug Administration 5630 Fishers Lane, Rm. 1061 Rockville, MD 20852 Re: FDA Docket No. FDA-2014-D-0758-0001 Draft Guidance for Industry on Distributing
More informationCreation of a pan-european Paediatric Clinical Trials Network. Heidrun Hildebrand (Bayer) & William Treem (Janssen),
Creation of a pan-european Paediatric Clinical Trials Network Heidrun Hildebrand (Bayer) & William Treem (Janssen), 19.12.2016 IMI webinar Need for public-private collaboration Due to European Regulation,
More informationTo begin from the beginning
POST-AUTHORISATION STUDIES IN EUROPE: BRIDGING THE GAP BETWEEN REGULATORY AND HEALTH TECHNOLOGY ASSESSMENT (HTA) STAKEHOLDER NEEDS BY BETTER DESIGN OF STUDIES Massoud Toussi Epidemiology, Europe Real World
More informationThe Right Data for the Right Questions:
The Right Data for the Right Questions: Evidentiary Needs as a Guide to Data Source Selection David Thompson, PhD Senior Vice President Louise Parmenter, PhD Global Head of Operations Real-World & Late
More informationRegulatory Pathways. Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB
Regulatory Pathways Devices vs. Drugs Are there roles for registries? John Laschinger, MD CDRH/ODE/DCD/SHDB johnlaschinger@fda.hhs.gov 1 Disclosures and Disclaimer John C. Laschinger, M.D. I am a full
More informationABOUT THE DUKE-MARGOLIS CENTER FOR HEALTH POLICY
ABOUT THE DUKE-MARGOLIS CENTER FOR HEALTH POLICY The Robert J. Margolis, MD, Center for Health Policy at Duke University is directed by Mark McClellan, MD, PhD, and brings together expertise from the Washington,
More informationNDA Requirements: Surveillance, Clinical Trial Data, Breakpoints
NDA Requirements: Surveillance, Clinical Trial Data, Breakpoints Kevin M. Krause Director Microbiology Achaogen, Inc. Presented at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of
More informationScientific Advisory Groups (SAG)
Scientific Advisory Groups (SAG) Experience and impact of patient involvement Presented by: Francesco Pignatti Human Medicines Evaluation Division, EMA Training session for patients and consumers involved
More informationA Path from RWD to RWE Stopping Over at Statistical Inference
A Path from RWD to RWE Stopping Over at Statistical Inference ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop 2018 Scott Snyder, PhD Director, Statistics and Data Science Cook Research
More informationUse of Big Data to Support Regulatory Decision Making
Use of Big Data to Support Regulatory Decision Making EMA-EuropaBio Annual Bilateral meeting Dr Alison Cave, Principal Scientific Administrator, Pharmacovigilance and Epidemiology Department An agency
More informationTHE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH
THE CONVERGENCE INITIATIVE TO MAXIMISE THE VALUE FROM EUROPEAN RESEARCH Georges De Moor EuroRec, Ghent University Electronic Health Records for Clinical Research 192 Growing number of Participating Projects
More informationStudy population The study population comprised patients undergoing major hip or knee surgery.
Pharmacoeconomic analysis of fondaparinux versus enoxaparin for the prevention of thromboembolic events in orthopedic surgery patients Dranitsaris G, Kahn S R, Stumpo C, Paton T W, Martineau J, Smith R,
More informationSurveillance Part 2. Marcia A. Testa, MPH, PhD Harvard School of Public Health
Surveillance Part 2 Marcia A. Testa, MPH, PhD Harvard School of Public Health Periodic Population-based Surveys Used for surveillance if surveys are repeated on a regular basis Careful attention to the
More informationUDI COMMUNITY (LUC): RESOURCES AND DELIVERABLES
LEARNING UDI COMMUNITY Advancing Health Care through Supply Chain Excellence LEARNING UDI COMMUNITY (LUC): RESOURCES AND DELIVERABLES Learning UDI Community WWW.AHRMM.ORG/LUC About AHRMM: The Association
More informationPragmatic Clinical Trials for Regulatory Decisions
Pragmatic Clinical Trials for Regulatory Decisions Jacqueline Corrigan-Curay, MD JD Office of Medical Policy Center for Drug Evaluation and Research FDA May 16, 2018 Pragmatic Clinical Trials Pragmatic
More informationMINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT
MINI-SENTINEL METHODS PROPENSITY SCORE MATCHING TOOL ENHANCEMENTS REPORT Prepared by: Joshua J Gagne, PharmD, ScD, 1 Martin Kulldorff, PhD, 4 Shirley V. Wang, PhD, ScM, 1 Ivair Silva, PhD, 6 Bruce Fireman,
More informationUpdate on Real World Evidence Data Collection
Update on Real World Evidence Data Collection STAMP, 10 March 2016 Presented by Dr Peter Arlett EMA An agency of the European Union What is Real-world evidence? Big data = umbrella term describing large
More informationComparative Effectiveness Research and Personalized Medicine: Policy, Science and Business. Setting the Stage. October 28, 2009 Washington, DC
Comparative Effectiveness Research and Personalized Medicine: Policy, Science and Business Setting the Stage October 28, 2009 Washington, DC Clifford Goodman, PhD Vice President clifford.goodman@lewin.com
More informationBiomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine
Biomarker Tests for Molecularly Targeted Therapies Key to Unlocking Precision Medicine Report from the National Academy of Medicine Robert Nussbaum MD Chief Medical Officer, Invitae Corporation Former
More informationFDA from a Former FDAer: Secrets and insights into regulatory review and drug development
FDA from a Former FDAer: Secrets and insights into regulatory review and drug development Andrew E. Mulberg, MD, FAAP Vice-President, Global Regulatory Affairs; Former Division Deputy, DGIEP, U.S. FDA
More informationInterpreting Composite Endpoints in Cardiovascular in Clinical Trials
Interpreting Composite Endpoints in Cardiovascular in Clinical Trials Concepts and Controversies Paul W Armstrong MD ACC Rockies Banff Alberta March 13 2017 Disclosure Statement Paul W. Armstrong MD Research
More informationOur comments include three recommendations and the associated rationale:
June 26, 2009 Dr. David Blumenthal Office of the National Coordinator for Health Information Technology Department of Health and Human Services 200 Independence Avenue, SW Washington, DC 20201 Dear Dr.
More informationNatalia Nayanova Director of Clinical Operations and General Manager. Accell Clinical Research 2016
Natalia Nayanova Director of Clinical Operations and General Manager Accell Clinical Research 2016 PRESENTATION STRUCTURE Company overview Advantages of the Region FDA & EMA Acceptance Myths vs. Realities
More informationAdvance Topics in Pharmacoepidemiology. Risk Management. Conflict of Interest Declaration. Benefit Harm Profile?
Advance Topics in Pharmacoepidemiology Risk Management 2012 Mid-Year ISPE Meeting Miami, April 21-23, 2012 Ariel E., Arias MD, PhD - Fac. Pharmacy; Université de Montréal - Biologics & Genetic Therapies
More informationPASS-PAES-HTA studies
PASS-PAES-HTA studies A view from academia Nicholas Moore University of Bordeaux Disclosure 2 Conflict of interest statement I & my department have worked or are working with, or have received various
More informationUse of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices Draft Guidance
More informationThe Role of Public-Private Partnerships & Evidence Generation
The Role of Public-Private Partnerships & Evidence Generation Christina Donatti LLB, BSc, MSc, PsyD IMI Lead, RWE EMEA Strategic Organisation. Janssen Cilag Janssen is proud to feature artwork created
More informationADAPTIVE PATHWAYS WORKSHOP
ADAPTIVE PATHWAYS WORKSHOP Stockholm Friday, November 10, 2017 9:00 13:00 Adaptive Pathways Applications for Scientific Insights in Europe PRESENTED BY: An ICON plc Company Agenda Overview 9:00 9:10 9:10
More informationUSTGlobal. Big Data Analysis Revolutionizing Healthcare Industry
USTGlobal Big Data Analysis Revolutionizing Healthcare Industry UST Global Inc, October 2017 Table of Contents Introduction The latest trends in healthcare point towards digitalizing the industry, with
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationSOURCES OF AND METHODS TO REDUCE BIAS IN NON-EXPERIMENTAL STUDIES BRIAN D. BRADBURY, DSC CENTER FOR OBSERVATIONAL RESEARCH
SOURCES OF AND METHODS TO REDUCE BIAS IN NON-EXPERIMENTAL STUDIES BRIAN D. BRADBURY, DSC CENTER FOR OBSERVATIONAL RESEARCH DIFFERENCES IN TREATMENT ASSIGNMENT DETERMINATION BETWEEN EXPERIMENTAL AND NON-EXPERIMENTAL
More informationModels of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics
Models of Industry Trials for Regulatory Purposes (Safety) Frank Cerasoli, PhD OREXIGEN Therapeutics Safety Evaluation is Not Completed at Approval Phase 3 programs evaluate efficacy and general safety/tolerability
More informationPROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective
PROTECT s Impact on Pharmacovigilance Practice: An Industry Perspective Robert Reynolds, ScD Vice President, Epidemiology Pfizer Research & Development ICPE Boston August 25, 2015 Disclosures I am an employee
More informationPRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM
PRAGMATIC TRIALS AND THE LEARNING HEALTHCARE SYSTEM INSIGHTS FROM YEAR 1 OF THE NIH COLLABORATORY Sean R. Tunis MD, MSc September 27, 2013 President and CEO Faculty/Presenter Disclosure Speaker Sean Tunis
More informationWINTHER TRIAL: AN SME DRIVEN EUFP7 PROGRAM TO CREATE AN INDUSTRY STANDARD TOOL TO OPTIMIZE THERAPEUTIC DECISION MAKING
WINTHER TRIAL: AN SME DRIVEN EUFP7 PROGRAM TO CREATE AN INDUSTRY STANDARD TOOL TO OPTIMIZE THERAPEUTIC DECISION MAKING Mohammad Afshar, MD, PhD Ariana Pharma WIN Symposium June 2015 - Paris Disclosure
More informationUse of RWE in a regulatory context: issues and examples. Rob Hemmings, MHRA
Use of RWE in a regulatory context: issues and examples Rob Hemmings, MHRA Disclaimer I don t particularly like the terms real world data, real world evidence. To be more precise, I will discuss data generated
More informationAvoiding Conflict of Interest Recognize and Manage COI
Avoiding Conflict of Interest Recognize and Manage COI December 2017 Udo Hoffmann, MD, MPH Professor of Radiology, Harvard Medical School Chief, Division of Cardiovascular Imaging, Director Cardiac MR
More informationLarge, Simple Trials Policy Needs: Ethics, Trial Processes
Large, Simple Trials Policy Needs: Ethics, Trial Processes Conflicts I have and continue to conduct simple and complex trials funded by industry, NIH and foundations Industry relations can be found at
More informationUse of real world data pre-authorisation what can it answer?
Use of real world data pre-authorisation what can it answer? Peter Mol -Principal assessor CBG-MEB -SAWP vice-chair (EMA) -Assistant professor, Clinical Pharmacy and Pharmacology, UMC Groningen Disclaimer
More informationPHARMA CONGRESS. Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments. October 28, 2008
PHARMA CONGRESS October 28, 2008 Pharmacovigilance and Drug Safety: Assessing Future Regulatory and Compliance Developments Beverly H. Lorell, MD Senior Medical & Policy Advisor King & Spalding LLP Assessing
More informationInterfacing Insights. What is Your Data Integrity Model?
Interfacing Insights What is Your Data Integrity Model? Demand for healthcare interfaces is rising, and there is a rapid pace in which healthcare entities are working to connect various internal applications
More informationSentinel Journey from Safety Question to Regulatory Action. Rima Izem, PhD
Sentinel Journey from Safety Question to Regulatory Action Rima Izem, PhD rima.izem@fda.hhs.gov Food and Drug Administration Center for Drug Evaluation and Research Division of Biometrics 7 1 Disclaimer
More informationRegistry Assessment of Peripheral Interventional Devices (RAPID)
Registry Assessment of Peripheral Interventional Devices (RAPID) Pablo Morales, MD FDA Division of Cardiovascular Devices MDEpiNet Annual Meeting October 20, 2017 RAPID moving into full SPEED Pablo Morales,
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More information10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.
Wednesday October 10, 2012 Please be sure to sign in and take copies of each handout. 1 Alicia Joy, IRB 2 FH Office of Research Administration Christina Jackson, BSN, RN, CCRC, CHRC 1 ClinicalTrials.gov
More informationEMA - Early Access. PEARRL Annual Meeting 2017-Regulatory Science Symposium. University College Cork, Ireland
EMA - Early Access PEARRL Annual Meeting 2017-Regulatory Science Symposium University College Cork, Ireland Presented by Evangelos Kotzagiorgis Scientific Administrator, Quality of Medicines Office Specialised
More informationBREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D
BREAKTHROUGH INNOVATION: LESSONS FOR PHARMA R&D Novasecta: Specialist Pharmaceutical Management Consulting The realities of unrelenting price pressure and patent expiries put a special pressure on pharmaceutical
More informationRegulatory Requirements
Regulatory Requirements CTTI Quality by Design Workshop 28-29 Jan 2013 Rockville, MD Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency An agency of the European Union Disclaimer
More informationMoving UDI from Regulation to Value Within Hospitals and Beyond
Moving UDI from Regulation to Value Within Hospitals and Beyond Karen Conway Executive Director, Industry Relations, GHX Terrie Reed, MDEpiNet Coordinating Center Duke Clinical Research Institute Slide
More informationNot My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center
Not My Study Challenges of Clinical Trial Disclosure at an Academic Medical Center Office of Research Compliance and Quality Assurance Yolanda P. Davis Sr. Research Compliance Officer Author: Yolanda P.
More informationA Rapid-Learning Health System
A Rapid-Learning Health System Using HIT for Medical Research Lynn Etheredge March 17, 2009 Rapid Breakthrough Science Using IT A new international model for science Large computerized research databases
More informationThe European Health Data & Evidence Network
The European Health Data & Evidence Network What is it? Nigel Hughes EFPIA Coordinator Scientific Director, JCI Patient Data for Research, Janssen 18 th May 2018 1 All too often real world research is
More information